CMS Reverses Reimbursement Changes for Bone Growth Stimulators
OFIX is trading near its 52-week low of $8.85 (12% above the low).
Summary
Orthofix Medical Inc. announced that CMS has reversed its recent changes to Medicare reimbursement for non-invasive bone growth stimulators, restoring prior payment rates and mitigating a significant financial headwind.
Key Events · Product Development and Regulatory · OFIX
-
CMS Reverses Reimbursement Changes
The Centers for Medicare & Medicaid Services (CMS) has withdrawn its modified billing requirements and fee schedule for non-invasive bone growth stimulators, which were initially changed following an FDA reclassification on April 16, 2026.
-
Reimbursement Rates Restored
Devices furnished on or after May 18, 2026, will now be processed and paid consistent with the treatment in effect prior to the FDA reclassification, restoring previous reimbursement rates.
-
Potential Impact on Guidance
This reversal mitigates a prior financial headwind, potentially impacting the company's previously lowered full-year 2026 financial guidance and withdrawn long-term targets announced on May 21, 2026.
Analysis · OFIX · Industrial Applications And Services
This filing announces that the Centers for Medicare & Medicaid Services (CMS) has withdrawn its recent changes to billing and fee schedule treatment for non-invasive bone growth stimulators. This means reimbursement rates for these devices will revert to the levels in effect before May 18, 2026, effectively reversing a potential negative impact on Orthofix's revenue from this product line. This development could lead to a revision of the company's previously lowered financial guidance from May 21, 2026.
At the time of this filing, OFIX was trading at $9.94 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $401.8M. The 52-week trading range was $8.85 to $16.99. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.